We must accept finite disappointment,
but never lose infinite hope — Martin Luther King, Jr
Well, in a word, no. At least, not so far .....
After that buoyant moment of happy hope and misty dreams, there followed what I’d sadly predicted would probably come …. the medical community started down the well-trod and all too-familiar to so many of us path of “ …..all in their heads …..", “ …..psychological reaction …..”, “ ….unreliable anecdotal evidence …”, yadda yadda yadda, blah blah blah.
So it was a pleasant surprize to come across this redacted report on a study that seems to have produced beneficial effects for an, admittedly, small group of patients, but results nonetheless, and something’s better than what we’ve been given so far, and more substantial ….
Here it is, see what you think, and by all means, please do send all complaints to …
COMPLAINTS ABOUT WHATEVER
OPEN 24 HOURS
PO Box H1-55Y,
Whining River Falls,
Northwest Territories,
Canada
OPEN 24 HOURS
PO Box H1-55Y,
Whining River Falls,
Northwest Territories,
Canada
Potential New Treatment for “Brain Fog” in Long COVID Patients
https://neurosciencenews.com/covid-brain-fog-treatment-22099/
“Guanfacine, developed in the lab of Amy Arnsten, PhD, Albert E. Kent
Professor of Neuroscience and professor of psychology, was approved
by the Food and Drug Administration (FDA) for the treatment of ADHD
in 2009, but clinicians have also used it extensively off-label for other
prefrontal cortical disorders such as traumatic brain injury (TBI) and PTSD.
Now, Arnsten has joined forces with Arman Fesharaki-Zadeh, MD, PhD,
assistant professor of psychiatry and of neurology, who has been treating
long COVID patients with a combination of guanfacine and N-acetylcysteine
(NAC), an anti-oxidant also used for the treatment of TBI.”
Professor of Neuroscience and professor of psychology, was approved
by the Food and Drug Administration (FDA) for the treatment of ADHD
in 2009, but clinicians have also used it extensively off-label for other
prefrontal cortical disorders such as traumatic brain injury (TBI) and PTSD.
Now, Arnsten has joined forces with Arman Fesharaki-Zadeh, MD, PhD,
assistant professor of psychiatry and of neurology, who has been treating
long COVID patients with a combination of guanfacine and N-acetylcysteine
(NAC), an anti-oxidant also used for the treatment of TBI.”